Healthcare

BIVI Research Note — Clinical Optionality Meets Financing Pressure
Research Notes

BioVie’s Phase 2 optionality faces going-concern pressure, fragile liquidity and persistent weakness against the broader biotechnology group.

BIVI Deep Coverage Review — Analysis as of July 24, 2026
Stocks

BioVie’s two Phase 2 readouts face a prior late-stage failure, funding pressure, fragile liquidity and persistent weakness versus biotech peers.